Simedx
1 known investors
SIME builds AI-powered point-of-care diagnostics for intensive care, starting with a test that analyzes gastric aspirate samples in the NICU using spectroscopy and AI to detect biochemical signatures of newborn lung maturity within minutes of birth. The compact, reagent-free platform is designed for NICU and ICU clinical workflows to support triage, earlier treatment, and fewer unnecessary admissions.
Investors Β· 1
Frequently asked questions
- What does Simedx do?
- SIME builds AI-powered point-of-care diagnostics for intensive care, starting with a test that analyzes gastric aspirate samples in the NICU using spectroscopy and AI to detect biochemical signatures of newborn lung maturity within minutes of birth. The compact, reagent-free platform is designed for NICU and ICU clinical workflows to support triage, earlier treatment, and fewer unnecessary admissions.
- Who are Simedx's investors?
- Simedx's investors include Oxford Technology Management.